Related Experiment Video
Updated: Jul 26, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Renal Vein Thrombosis Treated With Apixaban in a Patient With COVID-19: A Case Report
Tigran Kakhktsyan1, Aliaa Mousa1, Hassaan Arshad1
1Internal Medicine, Capital Health Regional Medical Center, Trenton, USA.
Abstract:
Renal vein thrombosis (RVT) is a rare condition characterized by the formation of a blood clot in one or both of the renal veins. Bilateral involvement is more common, but when the condition affects only one side, it usually occurs on the left due to more extensive venous vasculature compared to the right side. RVT can be caused by various factors such as trauma, dehydration, malignancy, and a hypercoagulable state. Acute RVT is typically more severe than chronic, and it can cause symptoms such as renal infarction, acute kidney injury, renal failure, severe flank pain, and hematuria. Some cases of RVT have also been linked to coronavirus disease 2019 (COVID-19), which is widely recognized to induce a hypercoagulable state. The standard treatment for RVT is warfarin but in this case report, we describe a COVID-19 patient with RVT whose thrombus was successfully treated with direct-acting oral anticoagulant (DOAC) apixaban for six months.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis IV: Nursing Management
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Anticoagulant Drugs: Low-Molecular-Weight Heparins

